was analysed histologically and by 3 [H]thymidine incorporation. RNA expression levels were measured by qPCR. Results: When we crossed miR-146a -/-into hTNFtg mice, histological examination revealed a significant increase in synovial inflammation and even more striking a more than twofold increase in local bone destruction, due to increased generation of osteoclasts in the tarsal joints of miR-146a -/-/hTNFtg mice compared to hTNFtg mice. Interestingly, systemic bone loss was comparable in hTNFtg compared to miR-146a -/-/hTNFtg mice, suggesting an important local role of miR-146a. Indeed, we detected increased levels of IL-1β, TRAF6, a major target of miR-146a and RANKL, in addition the expression level of OPG was decreased locally in the paws of miR-146a -/-/hTNFtg compared to hTNFtg mice. By performing bone marrow transplants we could indeed show a pivotal role for miR-146a in mesenchymal cells in controlling local osteoclast generation and bone destruction. Analysis of important mesenchymal cells in arthritis, the synovial fibroblasts exhibited enhanced proliferation if miR-146a is missing, in vitro and in vivo. Moreover stimulation of these cells with IL-1β, a prominent cytokine in arthritis which was also shown to be negatively regulated by miR-146a, led to increased expression of RANKL and TRAF6 in miR-146a deficient synovial fibroblasts.
Conclusions: These data demonstrate an important mitigating role of the miR146a in inflammatory arthritis, most importantly in local bone destruction, by controlling mesenchymal expression of osteoclastogenic factors. This shows an important anti-inflammatory role of miR-146a, which might possibly be exploited for therapeutic purposes. and wild-type (WT) mice. Ankle joints were macroscopically scored for 7 days. At day 0, 2 and 7, ankle and knee joints were isolated for histology and immunohistochemistry.
Results: The course of arthritis was studied macroscopically and Mertk -/-mice had increased macroscopic ankle scores until day 4, compared to WT. Thereafter, Axl -/-mice developed more severe arthritis as compared to WT with enhanced macroscopic scores from day 4 until day 7. Histology of ankle joints showed significantly more inflammation in Mertk -/-mice at day 2 and increased arthritis pathology in Axl -/-mice at day 7, reflecting the macroscopic ankle scores. Histological analysis of ankle joints of Axl -/-Mertk -/-mice at day 7 showed enhanced pathology compared to both Axl -/-and WT mice, indicating an additive effect of Axl and Mer deficiency. In contrast to the ankle joints at day 7, enhanced macroscopic scores and arthritis pathology in knee joints of Mertk -/-mice, compared to WT mice, was observed at both day 2 and day 7. Axl -/-mice had comparable knee joint pathology compared to WT. To explain the discrepancy of Axl involvement between ankle and knee at day 7, we examined Axl expression in synovium before the onset of arthritis. The cells in the lining layer of ankle synovium were strikingly Axl positive whereas the synovium of the knee joints was Axl negative.
Conclusions:
The Mer receptor plays a protective role at the onset of arthritis whereas the Axl receptor takes over this role in established disease in ankle joints. In the knee joints, however, Mer but not Axl, plays a prominent protective role, likely due to the lack of Axl in naïve knee joints. These findings identify the TAM receptors Axl and Mer as protective in arthritis, dependent on the distinct anatomic location. It is tempting to speculate that these differences in topographically distinct synovial joints could, at least in part, explain the differential joint involvement in RA. Background: Monocytes are central to the initiation of inflammation and bone erosion in rheumatoid arthritis (RA). Therefore, understanding of molecular pathways regulation in monocytes, especially at the early stages of RA development, is of crucial importance as it may help to predict the progression to the full-blown disease. However, mechanisms of gene regulation in monocytes, particularly the pattern of microRNA molecules (miRNAs) expression which can be involved in regulation of several cellular inflammatory pathways, in early phases of RA (i.e. at undifferentiated arthritis-UA stage) are not fully characterized. Objectives: To investigate the pattern of miRNAs expression in monocytes that could serve as new biomarkers for RA development. Methods: Magnetically sorted monocytes from peripheral blood of 19 patients with UA served for total RNA isolation. Total RNA from both sample and reference was labelled with Hy3 and Hy5 fluorescent label, respectively, using the miRCURY LNA microRNA Hi-Power Labeling Kit (Exiqon, Denmark). Fluorescent labelled samples and a reference RNA sample were hybridized to the miRCURY LNA microRNA Array 7th Gen (Exiqon), followed by scanning by Microarray Scanner System (Agilent Technologies, USA). The image analysis was carried out using ImaGene 9 Software (Exiqon). Results: Out of 19 patients with UA enrolled in the study, 12 were verified for diagnosis after 4 years of follow-up (7 patients did not respond to the call for re-evaluation). Four patients developed full-blown RA (UA→RA patients), 6 patients remained still in UA phase (UA→UA patients), 1 patient was diagnosed as having Sjögren's Syndrome, and 1 undifferentiated connective tissue disease. Baseline characteristics of UA→RA vs UA→UA patients were as follows: age (median: 50.5, range 37-59 years vs 52.5, range 32-63 years), CRP (median: 9.0, range 1-22 mg/l vs 8.0, range 1-21 mg/l), ESR (median: 37.0, range 4-47 mm/h vs 34.0, range 15-44 mm/h) and swollen joins count (median: 3.0, range 1-9 vs 2.5, range 1-4). Following computational unsupervised analysis we identified 50 miRNAs in monocytes that have the largest variation across all patients samples. From these 50 miRNAs we selected several specific miRNA candidates on the basis of significantly changed expression in monocytes of UA→RA vs UA→UA patients. Predicted specific miRNAs targeting inflammatory genes in monocytes of UA→RA patients are: miR-483-3p (2.7-fold increased, p=0.009), miR-378d (4.1-fold decreased, p=0.0059), miR-371b-5p (52.8-fold increased, p=0.0381) miR-642b-5p (13.7-fold increased, p=0.0380), and miR-25-3p (1.8-fold decreased, p=0.0317). Additional validation of selected miRNAs candidates will be further performed using qPCR analysis. (1) which is characterized by an accelerated atherosclerosis. TNF, a key cytokine involved in the pathogenesis of RA, has been associated to RA atherosclerosis (2) . Moreover, MPs could also have a role in endothelial dysfunction contributing to atherosclerosis in RA patients. Objectives: The aim of this study was: 1) to evaluate TNF expression on RA-MPs. 2) to estimate the effects of serum RA-MPs on endothelial apoptosis and autophagy before and after in vivo and in vitro treatment with Etanercept. Methods: 15 RA patients were recruited from the Department of Rheumatology Sapienza University of Rome at baseline (T0) and after three months of therapy (T3) with Etanercept. A fasting blood sample was collected and centrifuged two times to obtain platelet-poor plasma rich in MPs. The resulting plasma was stained with Ab anti-TNF and analized by flow cytometry. In vitro effects of serum RA-MPs on endothelium were evaluated using human umbilical vein cell line EA.hy926. Cells were treated with RA-MPs purified at T0 and T3 and with RA-MPs in vitro treated with Etanercept. At the end of experiments apoptosis and autophagy were evaluated. Apoptosis was analyzed by flow cytometry using a FITC-conjugated annexin V and propidium iodide apoptosis detection kit; autophagy was analyzed by western blot for the expression level of the autophagic marker LC3-II. Results: Our results showed that MPs purified from RA patients at T0 expressed TNF on their surface and this expression decreased after three months of treatment with Etanercept (p=0.04). Moreover, serum RA-MPs at T0 significantly increased, in a dose-dependent manner, both apoptosis and autophagy levels in the human umbilical vein cell line EA. hy926 (p=0.005 and p=0.02, respectively versus untreated cells). After three months of treatment with Etanercept, RA-MPs were not able to significantly change these parameters.Finally, in vitro studies showed that RA-MPs treated with Etanercept significantly decreased surface expression of TNF and were no longer able to modulate apoptosis and autophagy in EA.hy926 cells.
Conclusions: Our data demonstrate that serum RA-MPs express TNF on their surface. Moreover, both in vivo and in vitro treatment with Etanercept interfere with the ability of MPs to significantly modulate apoptosis and autophagy of endothelial cells by decreasing surface expression of TNF. References: [1] Background: Autophagy has emerged as a key mechanism in the development, survival and function of immune cells and dysregulation of autophagic pathway has been implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) (1). In fact, autophagy seems to be involved in the generation of citrullinated peptides, with consequent breakage of tolerance in RA (2) . Moreover, increased autophagy levels and a reduction of apoptosis-related molecules have been found in RA synovial tissues and a role of TNF-induced autophagy in RA development has been proposed (3). Objectives: The aim of the study was to analysed the effect of TNF and anti-TNF inhibitor etanercept on autophagy and apoptosis in cells involved in RA pathogenesis. Methods: Peripheral blood mononuclear cells (PBMCs) and fibroblast-like synoviocytes (FLS) isolated from RA patients were cultured in presence of TNF and in serum deprivation state (starvation) for 4 hours and then etanercept, at concentration of 15 ug/mL, were added to the culture. After 24h cells were analyzed for levels of autophagy marker LC3-II by western blot and for percentage of annexin V-positive apoptotic cells by flow cytometry. Results: As expected, TNF and starvation induced autophagy on RA PBMC and FLS in dose-dependent manner after 24h of culture (p<0.05 in all experimental conditions). Moreover, the adding of etanercept caused a significant reduction of LC3-II levels (p=0.004) and an increase of apoptosis rate (p=0.002) after both pro-autophagic stimuli (p<0.05). Conclusions: We demonstrated for the first time an inhibitory effect of etanercept on autophagy activation of cells involved in RA pathogenesis. In addition, our findings suggest a crucial role of autophagy in RA cells survival.
